UMB Bank n.a. Purchases 553 Shares of Exelixis, Inc. (NASDAQ:EXEL)

UMB Bank n.a. raised its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 68.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,361 shares of the biotechnology company’s stock after purchasing an additional 553 shares during the period. UMB Bank n.a.’s holdings in Exelixis were worth $45,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in EXEL. V Square Quantitative Management LLC bought a new stake in Exelixis during the third quarter valued at $30,000. USA Financial Formulas bought a new position in shares of Exelixis in the 4th quarter worth $32,000. Brooklyn Investment Group acquired a new position in shares of Exelixis during the third quarter valued at about $42,000. Capital Performance Advisors LLP bought a new position in shares of Exelixis in the third quarter valued at approximately $61,000. Finally, Essex Investment Management Co. LLC purchased a new position in Exelixis during the 3rd quarter worth $74,000. 85.27% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on EXEL shares. Morgan Stanley upped their price objective on Exelixis from $26.00 to $28.00 and gave the company an “equal weight” rating in a research note on Friday, October 11th. Guggenheim reiterated a “buy” rating on shares of Exelixis in a research report on Wednesday. Piper Sandler lifted their price objective on Exelixis from $36.00 to $37.00 and gave the company an “overweight” rating in a research note on Monday, January 13th. HC Wainwright increased their target price on Exelixis from $29.00 to $40.00 and gave the company a “buy” rating in a research note on Friday, January 10th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $41.00 target price on shares of Exelixis in a report on Thursday. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Exelixis presently has a consensus rating of “Moderate Buy” and an average target price of $35.00.

Exelixis Trading Down 5.1 %

NASDAQ EXEL opened at $32.38 on Friday. Exelixis, Inc. has a 12 month low of $20.01 and a 12 month high of $37.59. The stock’s fifty day moving average price is $34.87 and its 200-day moving average price is $29.77. The stock has a market cap of $9.25 billion, a P/E ratio of 20.76, a P/E/G ratio of 0.72 and a beta of 0.53.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.36 by $0.04. The business had revenue of $539.50 million for the quarter, compared to analysts’ expectations of $490.31 million. Exelixis had a net margin of 22.43% and a return on equity of 20.99%. The business’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.10 EPS. As a group, analysts forecast that Exelixis, Inc. will post 1.74 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Exelixis news, EVP Dana Aftab sold 1,162 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $31.40, for a total transaction of $36,486.80. Following the sale, the executive vice president now directly owns 498,945 shares of the company’s stock, valued at $15,666,873. This trade represents a 0.23 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Patrick J. Haley sold 41,588 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $34.36, for a total value of $1,428,963.68. Following the completion of the transaction, the executive vice president now owns 288,665 shares of the company’s stock, valued at $9,918,529.40. The trade was a 12.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 314,736 shares of company stock valued at $10,849,110. 2.85% of the stock is owned by insiders.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.